| abstract |
The present disclosure provides a CD3 binding molecule that specifically binds to CD3, for example, a monospecific binding molecule that specifically binds to CD3 and a multispecific binding molecule (MBM) that specifically binds to CD3 and tumor-associated antigens; Conjugates comprising a CD3 binding molecule, and pharmaceutical compositions comprising the CD3 binding molecule and the conjugate are provided. The present disclosure further provides methods of using CD3 binding molecules, conjugates, and pharmaceutical compositions to activate T cells in a subject, eg, a subject having cancer or an autoimmune disease. The present disclosure further provides recombinant host cells engineered to express the CD3 binding molecule and methods of producing a CD3 binding molecule by culturing the host cell under conditions in which the CD3 binding molecule is expressed. |